Medicenna Therapeutics Corp. income statement MDNAF

Annual Quarterly

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2023
Mar 31, 2023
FY 2022
Mar 31, 2022
FY 2021
Mar 31, 2021
Weighted average shares, basic
65
+19.2%
54
+9.3%
50
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MDNAF (OTC)
Fiscal year ends
March 31
Incorporated in
Canada (Federal Level)
Headquarters
Toronto
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1807983

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.